Tumor-infiltrating lymphocyte therapy, or tumor infiltrating lymphocyte therapy/TIL therapy, is a cell-based immunotherapy that uses autologous tumor-reactive lymphocytes to augment endogenous anti-tumor responses. It is typically a multistep regimen that includes non myeloablative lymphodepletion before infusion and high dose interleukin 2 afterward, with the therapeutic effect coming from the transferred TIL product rather than direct cytotoxic drugs. Clinically, it is used for advanced melanoma and has also been optimized in a rare neuroendocrine cancer case, highlighting its role in difficult-to-treat solid tumors. Recent literature emphasizes that in advanced melanoma, the main toxicities are driven by the lymphodepletion chemotherapy and high-dose IL-2 rather than the TIL product itself. Overall, the approach is positioned as an optimized therapeutic strategy for checkpoint-resistant disease and personalized cancer care.
Advanced melanoma
- Autologous TIL therapy has been approved for patients with advanced melanoma refractory to first-line immune checkpoint inhibitors, supporting its role after checkpoint resistance. (PMID:41661081)
- A 2026 Clinical Cancer Research review (PMID:41661081) describes TIL therapy as part of a broader strategy to redefine treatment options against checkpoint resistance.
- A 2026 Journal for Immunotherapy of Cancer study mapped the toxicity landscape in advanced melanoma and found adverse events were mainly associated with non myeloablative lymphodepletion and high dose interleukin 2, not the TIL product itself. (PMID:41956543)
- The toxicity analysis in advanced melanoma helps clarify the safety profile of the multistep autologous cell therapy regimen. (PMID:41956543)
Neuroendocrine cancer
- TIL therapy was optimized for a rare neuroendocrine cancer patient in an organoid-based whole-journey clinical mapping study. (PMID:41733805)
- The 2026 Cellular Oncology report (PMID:41733805) highlights personalized drug opportunity discovery alongside optimized tumor infiltrating lymphocyte therapy for this rare cancer setting.
- This case supports the feasibility of adapting cell-based immunotherapy to uncommon neuroendocrine malignancies. (PMID:41733805)
- The study frames TIL therapy as an optimized therapeutic approach in a reported rare cancer case. (PMID:41733805)